Skip to content

Meet TCG
Our Portfolio
In the News
Join our Ecosystem

Contact Us
Investor Login

Contact Us
Investor Login

Karina Tin

Dr. Millie Ray Promoted from Principal to Partner

TCG News / By Karina Tin

The Column Group announces the promotion of Dr. Millie Ray from Principal to Partner. Dr. Ray has been with TCG since 2017.

Dr. Millie Ray Promoted from Principal to Partner Read More »

Synthekine Announces Publication of Preclinical Data Demonstrating In Vivo Control of CD19 CAR-T Cells with its Orthogonal IL-2 System

Portfolio News / By Karina Tin

December 23, 2021

Synthekine Announces Publication of Preclinical Data Demonstrating In Vivo Control of CD19 CAR-T Cells with its Orthogonal IL-2 System Read More »

Remix Therapeutics Appoints Zaven Kaprielian, Ph.D., as Chief Scientific Officer

Portfolio News / By Karina Tin

December 15, 2021

Remix Therapeutics Appoints Zaven Kaprielian, Ph.D., as Chief Scientific Officer Read More »

Neurona Therapeutics Announces C-Suite Leadership Team

Portfolio News / By Karina Tin

December 13, 2021

Neurona Therapeutics Announces C-Suite Leadership Team Read More »

ORIC Pharmaceuticals Presents Data Supporting the Therapeutic Potential of ORIC-533 in Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting

Portfolio News / By Karina Tin

December 13, 2021

ORIC Pharmaceuticals Presents Data Supporting the Therapeutic Potential of ORIC-533 in Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting Read More »

Nurix Therapeutics Announces Regulatory Clearance to Initiate Phase 1 Clinical Trial of NX-5948 and Presents New Preclinical Data at the American Society of Hematology Annual Meeting

Portfolio News / By Karina Tin

December 12, 2021

Nurix Therapeutics Announces Regulatory Clearance to Initiate Phase 1 Clinical Trial of NX-5948 and Presents New Preclinical Data at the American Society of Hematology Annual Meeting Read More »

NGM Bio Announces Clinical Trial Collaboration with Merck Related to Ongoing Phase 1/2 Trial of NGM707, an ILT2/ILT4 Dual Antagonist Antibody, in Combination with Merck’s KEYTRUDA® (pembrolizumab)

Portfolio News / By Karina Tin

December 6, 2021

NGM Bio Announces Clinical Trial Collaboration with Merck Related to Ongoing Phase 1/2 Trial of NGM707, an ILT2/ILT4 Dual Antagonist Antibody, in Combination with Merck’s KEYTRUDA® (pembrolizumab) Read More »

Neurona Therapeutics to Present New Preclinical Data and Clinical Trial Plans for Lead Neural Cell Therapy Program, NRTX-1001, at the Annual Meeting of the American Epilepsy Society

Portfolio News / By Karina Tin

December 3, 2021

Neurona Therapeutics to Present New Preclinical Data and Clinical Trial Plans for Lead Neural Cell Therapy Program, NRTX-1001, at the Annual Meeting of the American Epilepsy Society Read More »

eFFECTOR Therapeutics Announces Publication of Zotatifin Preclinical Data in Frontiers in Oncology

Portfolio News / By Karina Tin

November 24, 2021

eFFECTOR Therapeutics Announces Publication of Zotatifin Preclinical Data in Frontiers in Oncology Read More »

Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Meeting 2021, the Annual Meeting of the American Association for the Study of Liver Diseases

Portfolio News / By Karina Tin

November 15, 2021

Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Meeting 2021, the Annual Meeting of the American Association for the Study of Liver Diseases Read More »

← Previous 1 … 39 40 41 … 59 Next →

Meet TCG
Our Portfolio
In The News
Join Our Ecosystem
Contact Us
Investor Login

Meet TCG
Join Our Ecosystem
Our Portfolio
Contact Us
In The News
Investor Login

Copyright © 2025. The Column Group

Privacy Policy
Terms of Use

Scroll to Top